These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29294265)

  • 1. [The role of NOD-like receptors (NLRs) in the pathogenesis of metabolic diseases].
    Grzywa RH
    Postepy Biochem; 2017; 63(3):205-209. PubMed ID: 29294265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors.
    Khanmohammadi S; Ramos-Molina B; Kuchay MS
    Diabetes Metab Syndr; 2023 Jul; 17(7):102788. PubMed ID: 37302383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The function of NOD-like receptors in central nervous system diseases.
    Kong X; Yuan Z; Cheng J
    J Neurosci Res; 2017 Aug; 95(8):1565-1573. PubMed ID: 28029680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into Nod-like receptors (NLRs) in liver diseases.
    Xu T; Du Y; Fang XB; Chen H; Zhou DD; Wang Y; Zhang L
    Int J Physiol Pathophysiol Pharmacol; 2018; 10(1):1-16. PubMed ID: 29593846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease and risk of type 2 diabetes.
    Lallukka S; Yki-Järvinen H
    Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):385-95. PubMed ID: 27432073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
    Nakajima T; Naito H
    Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [NAFLD pathogenesis in the light of recent research].
    Banaszczak M; Stachowska E
    Postepy Biochem; 2017; 63(3):190-197. PubMed ID: 29294263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
    Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
    Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.
    Bril F; Cusi K
    Endocrinol Metab Clin North Am; 2016 Dec; 45(4):765-781. PubMed ID: 27823604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of NOD- like Receptors in Glioma Angiogenesis: Insights into future therapeutic interventions.
    Saxena S; Jha S
    Cytokine Growth Factor Rev; 2017 Apr; 34():15-26. PubMed ID: 28233643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications.
    Okubo H; Kushiyama A; Nakatsu Y; Yamamotoya T; Matsunaga Y; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Asano T
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer.
    Lau JKC; Zhang X; Yu J
    Adv Exp Med Biol; 2018; 1061():139-147. PubMed ID: 29956212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases].
    Halmos T; Suba I
    Orv Hetil; 2017 Dec; 158(52):2051-2061. PubMed ID: 29285942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
    Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
    Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.